Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

9 Jan 2014

Abstract excerpt

BACKGROUND: Spinal Muscular Atrophy (SMA) is one of the most common inherited causes of infant death and is caused by the loss of functional survival motor neuron (SMN) protein due to mutations or deletion in the SMN1 gene. One of the treatment strategies for SMA is to induce the expression of the protein from the homologous SMN2 gene, a rescuing paralog for SMA. METHODS AND RESULTS: Here we demonstrate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Muscle Physiology and Disorders
Share to Neurogenetic and Muscular Disorders Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24405637
DOI: 10.1186/1750-1172-9-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse modelsPMID 24405637Read ↗

Advances in Therapeutic Development for Spinal Muscular AtrophySemantic proximity Read ↗

Spinal muscular atrophy: mechanisms and therapeutic strategies.Semantic proximity Read ↗

Spinal muscular atrophies.Semantic proximity Read ↗

Spinal muscular atrophy: from gene to therapy.Semantic proximity Read ↗

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophySemantic proximity Read ↗

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophySemantic proximity Read ↗

Animal models of spinal muscular atrophySemantic proximity Read ↗

Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathwaySemantic proximity Read ↗

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compoundsSemantic proximity Read ↗

Spinal muscular atrophy: recent advances and future prospects.Semantic proximity Read ↗

VPA response in SMA is suppressed by the fatty acid translocase CD36Semantic proximity Read ↗

Spinal muscular atrophy and therapeutic prospects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.